KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Amortizatization of Intangibles: 2018-2025

Historic Amortizatization of Intangibles for Castle Biosciences (CSTL) over the last 4 years, with Sep 2025 value amounting to $905,000.

  • Castle Biosciences' Amortizatization of Intangibles fell 45.15% to $905,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year decrease of 23.66%. This contributed to the annual value of $6.7 million for FY2024, which is 21.74% up from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Amortizatization of Intangibles is $905,000, which was down 22.72% from $1.2 million recorded in Q2 2025.
  • Castle Biosciences' 5-year Amortizatization of Intangibles high stood at $1.7 million for Q2 2024, and its period low was $184,000 during Q3 2022.
  • Its 3-year average for Amortizatization of Intangibles is $1.4 million, with a median of $1.6 million in 2023.
  • Per our database at Business Quant, Castle Biosciences' Amortizatization of Intangibles spiked by 752.72% in 2023 and then slumped by 45.15% in 2025.
  • Over the past 4 years, Castle Biosciences' Amortizatization of Intangibles (Quarterly) stood at $1.2 million in 2022, then surged by 38.51% to $1.6 million in 2023, then fell by 1.65% to $1.6 million in 2024, then tumbled by 45.15% to $905,000 in 2025.
  • Its Amortizatization of Intangibles stands at $905,000 for Q3 2025, versus $1.2 million for Q2 2025 and $1.4 million for Q1 2025.